Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
NCT00002067 · View on ClinicalTrials.gov ↗
Study Summary
To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.
Conditions Studied
Interventions
- DRUG Megestrol acetate
Study Locations (14)
California
- Dr Mark Goldstein — Los Angeles
- Summitt Med Ctr / San Francisco Gen Hosp — Oakland
- Palo Alto Veterans Adm Med Ctr / Stanford Univ — Palo Alto
- Eisenhower Med Ctr — Rancho Mirage
- UCD Med Ctr — Sacramento
- San Francisco AIDS Clinic / San Francisco Gen Hosp — San Francisco
- San Francisco Veterans Administration Med Ctr — San Francisco
Florida
- Miami Veterans Administration Med Ctr — Miami
- Univ of South Florida — Tampa
New York
- Mem Sloan - Kettering Cancer Ctr — New York
- SUNY / Health Sciences Ctr at Syracuse — Syracuse
Colorado
- Denver Public Health Dept — Denver
Illinois
- Northwestern Univ Med School — Chicago
Washington
- Northwest Family Ctr at the Harbor View Med Ctr — Seattle
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002067
The ClinicalTrials.gov registry entry for NCT00002067 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 504 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention — of which Megestrol acetate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00002067 reports 14 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00002067 about?
NCT00002067 is a clinical study titled "A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia". To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients ...
What is the current status of trial NCT00002067?
This trial is currently completed. It is a Phase 3 study.
What conditions does trial NCT00002067 study?
This clinical trial studies the following conditions: HIV Infections, Cachexia, Anorexia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00002067?
The interventions under investigation include: Megestrol acetate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00002067?
This trial is sponsored by Bristol-Myers Squibb, which has 504 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00002067 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.